Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Darunavir/cobicistat (Rezolsta®) is recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults and in adolescents (aged 12 years and older, weighing at least 40 kg). |
|||
|
|||
Medicine details |
|||
| Medicine name | darunavir / cobicistat (Rezolsta®) | ||
| Formulation | 800 mg / 150 mg film-coated tablet | ||
| Reference number | 3779 | ||
| Indication | In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg) |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1220 | ||
| NMG meeting date | 07/10/2020 | ||
| AWMSG meeting date | 11/11/2020 | ||
| Date of issue | 13/11/2020 | ||
| Further information This advice incorporates and replaces the AWMSG recommendation for darunavir/cobicistat (Rezolsta®) as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV 1) infection in adults aged 18 years or older (Advice number 2115, originally published September 2015). |
|||